The hinterland of familial hypercholesterolaemia: What do we not know?

Current Opinion in Lipidology

Volumn 26, Issue 6, 2015, Pages 475-483

  Wierzbicki, Anthony S ^a   Watts, Gerald F ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

cardiovascular disease; cardiovascular disease prevention; ezetimibe; familial hypercholesterolaemia; guideline; proprotein convertase subtilisin kexin 9 inhibitor; statin

Indexed keywords

CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG;

CALCULATION; CHOLESTEROL METABOLISM; ECHOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INTRAVASCULAR ULTRASOUND; LIPID METABOLISM; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCREENING; SOCIAL PSYCHOLOGY; FACTUAL DATABASE; HYPERLIPOPROTEINEMIA TYPE II; METABOLISM; TREATMENT OUTCOME;

DATABASES, FACTUAL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84957622864     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000238     Document Type: Review

References (87)

1. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168:1-14.
2. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490a.
3. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171:309-325.
4. Bell DA, Garton-Smith J, Vickery A, et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia. Heart Lung Circ 2014; 23:309-313.
5. Foody JM. Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice. Clin Cardiol 2014; 37:119-125.
6. Withycombe B, Winden JC, Hassanyn R, et al. The extent of familial hypercholesterolemia instruction in US schools and colleges of medicine, pharmacy, and osteopathic medicine. J Clin Lipidol 2015; 9:281-288.
7. Kirke AB, Barbour RA, Burrows S, et al. Systematic detection of familial hypercholesterolaemia in primary healthcare: a community based prospective study of three methods. Heart Lung Circ 2015; 24:250-256.
8. World Health Organisation. Familial hypercholesterolemia (FH): report of a second WHO consultation. Geneva, Switzerland: World Health Organisation; 1999; 1-16.
9. National Institute of Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. National Institute of Health and Clinical Excellence; 2008; 1-48.
10. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337:a1095.
11. Expert panel on detection evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89:1333-1445.
12. Expert panel on detection evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). Executive summary of the third report of The National Cholesterol Education Program (NCEP). JAMA 2001; 285:2486-2497.
13. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S1-S8.
14. Ito MK, McGowan MP, Moriarty PM, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S38-S45.
15. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956-3964.
16. Watts GF, Shaw JE, Pang J, et al. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol 2015; 185:69-71.
17. Shi Z, Yuan B, Zhao D, et al. Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population. Int J Cardiol 2014; 174:834-836.
18. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36:560-565.
19. Miller PE, Martin SS, Toth PP, et al. Screening and Advanced Lipid Phenotyping in Familial Hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). J Clin Lipidol 2015; 9:676-683.
20. Varvel SA, Voros S, Thiselton D, et al. Familial hypercholesterolemia prevalence of 1.5% in a clinical database of 542 214 patients: refined risk stratification using apoB:LDL-C ratio. J Clin Lipidol 2015; 9: 414.
21. De Backer G, Besseling J, Chapman J, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 2015; 241:169-175.
22. Ooi EM, Barrett PH, Watts GF. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies. Int J Cardiol 2013; 168:1811-1818.
23. Huijgen R, Kindt I, Defesche JC, Kastelein JJ. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. Eur Heart J 2012; 33:2325-2330.
24. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943-949.
25. Civeira F, Jarauta E, Cenarro A, et al. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. J Am Coll Cardiol 2008; 52:1546-1553.
26. Futema M, Shah S, Cooper JA, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61:231-238.
27. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Lowdensity lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106:3031-3036.
28. Wiegman A, Rodenburg J, de Jongh S, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003; 107:1473-1478.
29. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63:1982-1989.
30. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274:1771-1774.
31. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128:2567-2576.
32. Hajhosseiny R, Sabir I, Khavandi K, Wierzbicki AS. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future. Clin Pharmacol Ther 2014; 96:64-73.
33. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
34. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004; 4:97-104.
35. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011; 97:1175-1181.
36. Ademi Z, Watts GF, Juniper A, Liew D. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 2013; 167:2391-2396.
37. Marteau T, Senior V, Humphries SE, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A 2004; 128A:285-293.
38. Wald DS, Kasturiratne A, Godoy A, et al. Child-parent screening for familial hypercholesterolemia. J Pediatr 2011; 159:865-867.
39. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 2007; 335:599.
40. Morris JK, Wald DS, Wald NJ. The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet A 2012; 158A:78-84.
41. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1-S45.
42. Rabar S, Harker M, O'Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014; 349:g4356.
43. Sheppard JP, Fletcher K, McManus RJ, Mant J. Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study. Br J Gen Pract 2014; 64:e38-e46.
44. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324:939-942.
45. Hippisley-Cox J, Coupland C, Brindle P. Validation of QRISK2 (2014) in patients with diabetes. Nottingham, UK: QResearch Group; 2014.
46. Cederholm J, Eeg-Olofsson K, Eliasson B, et al. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med 2011; 28:1213-1220.
47. Watts GF, Pang J, Santos RD. Europe aspires to set the record straight on familial hypercholesterolaemia. Atherosclerosis 2015; 241:769-771.
48. Patel J, Al Rifai M, Blaha MJ, et al. Coronary artery calcium improves risk assessment in adults with a family history of premature coronary heart disease: results from Multiethnic Study of Atherosclerosis. Circ Cardiovasc Imaging 2015; 8:e003186.
49. Clarke RE, Padayachee ST, Preston R, et al. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart 2013; 99:175-180.
50. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303:893-896.
51. Mundal L, Sarancic M, Ose L, et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J Am Heart Assoc 2014; 3:e001236.
52. Besseling J, Kindt I, Hof M, et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 2014; 233:219-223.
53. Sijbrands EJ, Westendorp RG, Defesche JC, et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001; 322:1019-1023.
54. Stallones RA. The rise and fall of ischemic heart disease. Sci Am 1980; 243:53-59.
55. Starr BJ, Hadfield G, Hutten BA, et al. Development of sensitive and specific age- and gender specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008; 46:791-803.
56. de Sauvage Nolting PR, Defesche JC, Buirma RJ, et al. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003; 253:161-168.
57. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010; 341: c6624.
58. Huijgen R, Vissers MN, Kindt I, et al. Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes. Circ Cardiovasc Genet 2011; 4:413-417.
59. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ 2015; 350:h1035.
60. Toleikyte I, Retterstol K, Leren TP, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation 2011; 124:1606-1614.
61. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36:2425-2437.
62. Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 2014; 312:1055-1057.
63. Belamarich PF. Point/counterpoint: is universal screening and treatment of hypercholesterolemia in children justified? No: the evidence does not supports universal screening and treatment. J Clin Lipidol 2015; 9.
64. Huijgen R, Homsma SJ, Hutten BA, et al. Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study. Eur J Hum Genet 2012; 20:722-728.
65. Neil HA, Hammond T, Mant D, Humphries SE. Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ 2004; 328:500-501.
66. Kramer A, Jansen AC, van Aalst-Cohen ES, et al. Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia. BMC Public Health 2006; 6:262.
67. Jakulj L, Vissers MN, Rodenburg J, et al. Plant stanols do not restore endothelial function in prepubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. J Pediatr 2006; 148:495-500.
68. Besseling J, Kastelein JJ, Defesche JC, et al. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015; 313:1029-1036.
69. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337:a2423.
70. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-581.
71. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305:2556-2564.
72. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385:351-361.
73. Charles Z, Pugh E, Barnett D. Ezetimibe for the treatment of primary (heterozygous-familial and nonfamilial) hypercholesterolaemia: NICE technology appraisal guidance. Heart 2008; 94:642-643.
74. Hadfield SG, Horara S, Starr BJ, et al. Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project. Ann Clin Biochem 2008; 45:199-205.
75. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-1443.
76. Wierzbicki AS. The ezetimibe Jonah: the trials and tribulations of an unlucky drug. Int J Clin Pract 2011; 65:1207-1208.
77. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387-2397.
78. Phan BA, Moore AB, Davis J, et al. Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment: Observational Study (FATS-OS). J Clin Lipidol 2014; 8:489-493.
79. Ara R, Pandor A, Stevens J, et al. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Prev Cardiol 2012; 19:474-483.
80. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:341-350.
81. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128:2113-2120.
82. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146-2157.
83. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 2015; 13:123.
84. Lu L, Krumholz HM, Tu JV, et al. Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. Am Heart J 2014; 167:683-689.
85. Vickery AW, Bell D, Garton-Smith J, et al. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services. Heart Lung Circ 2014; 23:1158-1164.
86. Purchase S, Vickery A, Garton-Smith J, et al. A framework for bridging the gap in the care of familial hypercholesterolaemia in the community: pragmatic and economic perspectives. Int J Evid Based Healthc 2014; 12:244-254.
87. Krass I, Walker AT, Watts GF. Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist? Int J Clin Pharm 2012; 34:501-505.